Physician profile
Peter W Debry
NPI 1831137991
$10,306.98
in general payments reported to CMS, 2019-2025
26 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,184 · 2020: $555 · 2021: $1,477 · 2022: $1,290 · 2023: $2,242 · 2024: $816 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,302 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,302.30 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,677.55 | 2022-2025 | Xen Glaucoma Treatment System, Durysta, Vuity |
| Johnson & Johnson Surgical Vision, INC. | $1,809.65 | 2019-2023 | Tecnis Simplicity |
| Ivantis, INC | $1,105.73 | 2019-2021 | |
| Alcon Vision LLC | $846.11 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Glaukos Corporation | $692.77 | 2022-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Allergan, INC. | $609.61 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $376.06 | 2019-2021 | |
| Sight Sciences, INC. | $323.05 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $313.64 | 2019-2021 | |
| Rxsight INC | $251.14 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $222.49 | 2023-2025 | Miebo, Envista Mx60 Iol, Envista Envy Iol |
| Nova Eye, INC. | $184.06 | 2025 | |
| Microsurgical Technology, INC. | $160.06 | 2022 | |
| Amgen INC. | $157.94 | 2025 | Tepezza |
| Harrow Eye, LLC | $136.00 | 2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $131.19 | 2022-2025 | Iyuzeh |
| Sun Pharmaceutical Industries INC. | $82.78 | 2019-2020 | |
| Oyster Point Pharma, INC. | $52.11 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $50.85 | 2025 | Oxervate |
| Staar Surgical Company | $32.71 | 2019 | |
| New World Medical,INC. | $21.35 | 2020 | |
| Eyevance Pharmaceuticals LLC | $20.67 | 2023 | Flarex |
| Novartis Pharmaceuticals Corporation | $17.27 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $15.76 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $15.60 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Debry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.